A patent estate invented by Drs. Xiaoyuan Chen and Orit Jacobson and assigned to Molecular Targeting Technologies (MTTI) covers a radiotherapeutic with prospective applicability for treating Neuroendocrine Neoplasms. They are abnormal and excessive growth of tissue that arise from cells of the endocrine (hormonal) and nervous systems.  Although many are benign they can become malignant.  Most commonly found in the intestine, they are also found in the pancreas, lung and the rest of the body.  The annual incidence estimate varies but can be pegged at 2.5-5 per 100,000 population. https://link.springer.com/article/10.1007%2Fs10555-011-9292-1. The prevalence has been estimated at 35 per 100,000 and maybe considered higher if clinically silent tumors are included.  MTTI was granted the worldwide patent commercialization license by the National Institute of Biomedical Imaging and Bioengineering (an institute within the National Institutes of Health).  MTTI is a privately held venture with a predominantly pre-clinical pipeline—see http://www.mtarget.com/PIPE.html

Source: Oaoa

Pin It on Pinterest